Breaking

Crypto Market Update: Bitcoin Price Slide Continues, Kraken Files for IPO
Skyharbour Engages Emerging Markets Consulting LLC for Marketing Contract
Heliostar Presents Third Quarter 2025 Financial Results
Noble Mineral Closes its Non-Brokered Private Placement and Extends Warrants
Joe Cavatoni: Gold’s Key Driver Now, Plus 2026 Catalysts to Watch
Angkor Resources Advances Analysis of Andong Bor Drill Core
E-Power Resources Inc. Announces Tetepisca Flake Graphite Property Delivers High-Value Concentrate Potential, Demonstrating High Recoveries and Premium Flake Size Distribution
Admission to Trading on the OTCQB Venture Market in the United States

Facebook
Twitter
Google Plus
Instagram
Pinterest
Vimeo

Investing
Stock
Latest News
Editor’s Pick
Economy
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

By June 4, 2025

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Crypto Market Update: Bitcoin Price Slide Continues, Kraken Files for IPO

November 21, 2025

Skyharbour Engages Emerging Markets Consulting LLC for Marketing Contract

November 21, 2025

Heliostar Presents Third Quarter 2025 Financial Results

November 21, 2025

Enter Your Information Below To Receive Latest News, And Articles.
Your name

Your email
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest Posts
Categories
- Economy (1,025)
- Editor's Pick (633)
- Investing (5,100)
- Latest News (3,536)
- Stock (1,161)
About Rightinvestingway

Disclaimer: Rightinvestingway.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 Rightinvestingway.com

Top

Type above and press Enter to search. Press Esc to cancel.